Gut and liver
Cure8 research brief
Why This Matters
Growth impairment is a key concern in pediatric Crohn's disease; knowing which children are more likely to regain weight or height and how treatments like infliximab relate to growth can affect monitoring and treatment conversations.
Parents and clinicians may find the reported sex- and age-specific differences relevant when tracking growth and discussing therapeutic options.
Who Should Pay Attention
Pediatric patients with Crohn's disease and their parents/caregivers; pediatric gastroenterologists and clinicians managing growth in IBD; researchers studying treatment effects on growth outcomes.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study analyzed 2-year growth trajectories in 533 children with pediatric Crohn's disease from a nationwide Korean registry and reports sex- and age-specific differences in weight and height recovery. What the study reports: weight recovery was common during follow-up, while linear (height) recovery was limited overall.
Girls showed greater weight and height catch-up than boys. In multivariable models, baseline nutritional and inflammatory markers (weight z-score, platelet count, albumin, disease activity) predicted weight recovery; baseline height z-score predicted height recovery.
Treatment finding: generalized additive models in this cohort suggested an association between infliximab use and improved height recovery, especially in females younger than 14 years. The authors note this sex- and age-specific association warrants further study.
Study scope and limits: this brief is grounded in the article abstract from the journal Gut and Liver; Cure8 did not review full trial datasets or perform independent analysis. The finding of an association with infliximab is observational within registry data and does not prove causation.
Keep In Mind
This is an observational registry-based analysis (registered as KCT0008723) reported in the article abstract. Associations between infliximab and height recovery were seen in subgroup analysis and should be interpreted cautiously; randomized trial data would be needed to establish causality. The brief is based on the provided abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationGut and liver
AuthorsKim DU, Moon JS, Lee YJ +17 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedAug 31, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry.
Growth and nutrition are common concerns in children with IBD because poor weight gain and short stature can affect long‑term health and development.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Aminosalicylate use Increases Corticosteroid Exposure and Decreases Biologic Durability in Pediatric Crohn's Disease.
This study suggests that using 5‑ASA drugs early in children with Crohn’s disease was common but linked to more steroid use, delayed biologic treatment, and lower biologic durability — outcomes that matter for long‑term...
Characterization of a Large Hispanic Cohort With Inflammatory Bowel Disease Across a 26‐Year Span: The University of Puerto Rico Registry
This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.